With Allowance of US Patent Application, Veritas Aims to Outlicense RNAi Delivery Technology | GenomeWeb

Veritas Bio, a biotechnology holding company established by two co-founders of expressed RNAi firm Nucleonics, said this week that the US Patent and Trademark Office has issued a notice of allowance on a patent application covering a novel liver-directed RNAi delivery technology.

Poised to receive a patent on the technology, Veritas is now on the lookout for companies interested in licensing the delivery approach for use within their own RNAi research and development programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.